Dr. Venkata Y Behara, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 601 W Golf Rd, Suite 105, Mount Prospect, IL 60056 Phone: 847-298-0600 Fax: 847-298-6395 |
Dr. Shen Song, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 601 W Golf Rd Ste 105, Mount Prospect, IL 60056 Phone: 847-439-8780 |
Dr. Delin Wang, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 601 W Golf Rd Ste 105, Mount Prospect, IL 60056 Phone: 847-439-8780 |
Manish Tanna, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 601 W Golf Rd Ste 105, Mount Prospect, IL 60056 Phone: 847-439-8780 Fax: 847-439-8940 |
News Archive
CARLINA Technologies, a biotechnology company specialized in the development of nanomedicines, today announces the signing of a collaborative agreement with GenBiotech for the development of a prolonged-release pharmaceutical form of a protein. The resultant protein will be used in bone and cartilage repair. Financial details were not disclosed.
XenoPort, Inc. announced today that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid.
Human antibodies that thwart the SARS virus in mice can be mass-produced quickly using a new laboratory technique developed by an international research team collaborating with the National Institute of Allergy and Infectious Diseases (NIAID).
States eased those policies based on politics as much as COVID-19 death rates or case counts, according to new research from the University of Washington. The researchers also found that states with large Black communities, despite those communities being hit hardest by the pandemic, also lifted restrictions earlier.
Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.
› Verified 5 days ago